

PANcreatic CAncer Initial Detection via liquid biopsy

project start
1st January 2023

project duration
5 years

grant amount
9.8 million €






website
pancaid-project.eu



PANCAID is an international research consortium that aims to provide a minimally invasive **blood test** using a comprehensive panel of liquid biopsy diagnostics for the **early detection of pancreatic cancer**. Pancreatic cancer is usually diagnosed late and most patients die within one year.

Therefore, early detection and diagnosis is urgently needed.

Objectives

-  **Data acquisition and biobanking of blood samples** from individuals at risk, patients with intraductal papillary mucinous neoplasia, and patients with early pancreatic cancer
-  **Liquid biopsy diagnostics (LBx)** including the most relevant analytes currently available (circulating tumour (ct) DNA, exosomes, ct cells and host cells, circulating proteins and metabolites)
-  Combine results into a **multi-marker panel** via computation and artificial intelligence (AI) and validate the panel on independent cohorts of patients and individuals at risk
-  **Introduce the blood test into medical practice** by defining the target population for such a blood test from a socio-economic and ethical perspective
-  Design a prospective European **multi-centre study** aimed to demonstrate the **clinical utility of LBx** for individuals at high risk to develop pancreatic cancer

8 countries
16 partners
1 associated partner



Funded by
the European Union



Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

Photo credits: Rasi Bhadramani